Recombinant adenovirus p53 combined with radiotherapy improves efficacy and safety in the treatment of head and neck lymphoma

• Published in: Cancer biomarkers : section A of Disease markers Vol. 23; no. 2; pp. 213 - 220
• Main Authors: Xu, Yong-Hua, Liu, Shuo-Hui, Hao, Fu-Rong, Zhang, Yin-Huan
• Format: Journal Article
• Language: English
• Published: Netherlands IOS Press BV 01.01.2018
• Subjects: Adenoviridae - genetics; Adenoviruses; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; CD3 antigen; CD4 antigen; CD8 antigen; Combined Modality Therapy; Combined treatment; Effectiveness; Female; Gene therapy; Genetic Therapy; Genetic Vectors - administration & dosage; Genetic Vectors - genetics; Head and neck; Head and Neck Neoplasms - diagnosis; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - therapy; Humans; Injection; Interleukin 2; Interleukin 2 receptors; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma - diagnosis; Lymphoma - genetics; Lymphoma - therapy; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; p53 Protein; Patients; Radiation therapy; Radiotherapy; Reduction; Safety; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; Treatment Outcome; Tumor Suppressor Protein p53 - genetics; Tumors; Young Adult; Head and neck lymphoma; radiotherapy; adverse reaction; safety; efficacy; recombinant adenovirus p53
• ISSN: 1574-0153; 1875-8592
• DOI: 10.3233/CBM-181286

Lymphoma is considered to be a kind of malignant tumour. Gene therapy and radiotherapy have been reported as treatment methods for head and neck lymphoma. This study aims to evaluate the efficacy and safety for the treatment of head and neck lymphoma by a combination of recombinant adenovirus p53 (rAd-p53) and radiotherapy. A total of 156 patients with head and neck lymphoma were selected. All patients received an intratumor injection of rAd-p53 of four different doses, namely, 0, 1 × 1010 VP, 1 × 1011 VP and 1 × 1012 VP, once a week for 8 weeks, and radiotherapy was administered 3 days after the rAd-p53 injection using the same dosage and method. Four, eight and twelve weeks after treatment, tumor reduction and complete response (CR) rates, special laboratory examination and adverse reaction assessment were detected to evaluate the efficacy and safety of combined treatment with rAd-p53 injection and radiotherapy for head and neck lymphoma. At week 4, 8 and 12 of treatment with rAd-p53 at the 1 × 1010 VP, 1 × 1011 VP and 1 × 1012 VP doses, the average tumour reduction and CR rates were evidently elevated, the anti rAd-p53 antibody in the serum of patients was expressed positively, and the T cell subsets (CD3/CD4/CD8) increased and interleukin 2 receptor (IL-2R) level decreased markedly. Additionally, rAd-p53 was proven to be clinically safe in the treatment. Altogether, we conclude that rAd-p53 combined with radiotherapy improves the efficacy and safety in treating head and neck lymphoma, which has a broad scope in future clinical application.